ITGA4 and B-cell chronic lymphocytic leukemia: With the aim to establish the CD49d minimum expression levels that enable activation by anti-IgM, an additional set of experiments were performed using CLL cells from CD49d− cases (i.e., expressing CD49d below the 30% clinical cutoff).